Eli Lilly shifts clinical trial activity during coronavirus

By Jenni Spinner contact

- Last updated on GMT

(Image: Getty/Belyjmishka)
(Image: Getty/Belyjmishka)

Related tags: Coronavirus, Eli lilly and company, Clinical trials

The pharmaceutical company has announced several changes to its clinical trial activities in the face of the global pandemic.

Eli Lilly and Co. plans to delay the start of most planned new studies and pause enrollment in most of its studies that are ongoing. However, the company intends to continue currently occurring trials for already enrolled patients.

Global impacts

The company states the global coronavirus/COVID-19 has had a tremendous impact on the global healthcare system, including clinical trial operations. The majority of healthcare systems have had to make changes to their operations during the pandemic, including prioritizing care for coronavirus patients and limiting or stopping other functions.

The impacts of the virus also have impaired the ability of research sites to maintain its previous level of activity on studies, start new studies, or enroll new patients to trials.

Easing pressures

According to Tim Garnett, chief medical officer for Lilly, the company is doing its best to relieve some of the pressure the coronavirus has placed on healthcare infrastructure around the world.

We have repurposed our laboratories to conduct diagnostic testing for patients and we are researching potential therapeutics​,” he said. “By delaying most new study starts and pausing enrollment of new patients or healthy volunteers in most ongoing studies, we hope to ease the burden on participating healthcare facilities and allow physicians to focus more of their efforts on combatting COVID-19​."

Garnett added that while stopping enrollment of new patients will help ease the burden on the healthcare system, disrupting the activity of enrolled patients could be detrimental.

Lilly recognizes that for patients already enrolled in clinical trials, discontinuation would disrupt their treatment and potentially diminish the societal value of the research information to which they are contributing. Therefore, we will maintain ongoing studies, but with study-by-study consideration​," he said.

The company advises that study participants currently enrolled and continuing with trials should continue to follow the protocols of their studies, and to speak with their physicians about any lingering concerns they may have about participation.

Related news

Show more

Related products

show more

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

Standardizing data with NCI controlled terminology

Standardizing data with NCI controlled terminology

Formedix | 18-Jul-2022 | Technical / White Paper

The use of consistent terminology within and between studies is critical to enabling an efficient trial process. CDISC standards such as CDASH, SDTM, SEND...

Planning Your First-In-Human Trial

Planning Your First-In-Human Trial

Altasciences | 15-Jul-2022 | Technical / White Paper

A first-in-human (FIH) clinical trial is a significant milestone in the development of a potential new drug. A successfully conducted FIH trial provides...

Related suppliers

Follow us

Products

View more

Webinars